Streetbeat News

Products Services

ALNT

Allient Inc. has launched a new business unit, Allient Defense Solutions, to expand its presence in high-growth markets and enhance long-term customer value.

Portfolio Pulse from

December 11, 2024 | 9:30 pm

ULTA

Ulta Beauty, Inc. CEO Dave Kimbell presented at the Raymond James 2024 TMT & Consumer Conference, discussing the company's strategies and outlook.

Portfolio Pulse from

December 11, 2024 | 9:15 pm

CTSH

Beyond Bank Australia partners with Cognizant to modernize its IT infrastructure and improve operational resilience. This collaboration aims to lead the future of customer-owned banking.

Portfolio Pulse from

December 11, 2024 | 9:15 pm

BIOA

Levi & Korsinsky has initiated an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential securities fraud following the discontinuation of its STRIDES Phase 2 trial due to safety concerns.

Portfolio Pulse from

December 11, 2024 | 9:15 pm

V

Visa's network effect is driving its growth, with increased consumer and business adoption strengthening its ecosystem.

Portfolio Pulse from

December 11, 2024 | 9:15 pm

QCOM

The article discusses the potential impact on Qualcomm (QCOM) stock if Apple iPhones stop using Qualcomm modems. Despite this potential risk, Qualcomm's strong earnings history and favorable Zacks Rank suggest the stock is poised for further price appreciation.

Portfolio Pulse from

December 11, 2024 | 9:15 pm

GM

General Motors (GM) has decided to exit its Cruise robotaxi business, a move that most Wall Street analysts agree was necessary. However, this decision marks a disappointing end for a venture that was projected to generate $50 billion in revenue by 2030.

Portfolio Pulse from

December 11, 2024 | 9:00 pm

AAPL

AVGO

NVDA

Apple is collaborating with Broadcom to develop its own AI chips, potentially reducing its reliance on Nvidia. Additionally, Apple is launching Siri with ChatGPT integration.

Portfolio Pulse from

December 11, 2024 | 8:45 pm

RVPH

Reviva Pharmaceuticals is working on Brilaroxazine for schizophrenia treatment, showing promising Phase 3 data. However, the company faces financial challenges and needs funding for a second trial to meet FDA requirements. Upcoming announcements on safety and efficacy data are expected.

Portfolio Pulse from

December 11, 2024 | 8:45 pm

TGT

Target Test Prep has been recognized as the top resource for Executive Assessment preparation in 2024 by Consumer365, highlighting its effective and adaptable approach.

Portfolio Pulse from

December 11, 2024 | 8:45 pm